Adam Cuker, MD, MS, and Amit R. Mehta, MD, discuss the changing treatment landscape and patients goals when treating chronic immune thrombocytopenia.
Amitkumar Mehta, MD
Advertisement
Articles by Amitkumar Mehta, MD
Amitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Pant Discusses Next Steps in Daraxonrasib Development for Pancreatic Cancer
2
FDA Expands Sevabertinib Approval to Treatment-Naive HER2-Mutant NSCLC
3
Arlo-Cel Meets Efficacy End Point in Quadruple-Class Exposed Myeloma
4
Mipletamig Triplet Demonstrates Frontline Activity in TP53-Mutated AML
5